Smoking cessation (tobacco dependence; stop-smoking support, NRT & pharmacotherapy)
Bedside summary
Smoking is the single largest preventable cause of death. Every clinical contact is an opportunity to deliver very brief advice and offer evidence-based support, which combines behavioural support with pharmacotherapy and roughly triples quit success versus willpower alone. Use the 'Ask-Advise-Act' (or 5As) model. Pharmacotherapy options include nicotine replacement therapy (combination preferred), varenicline, bupropion and, increasingly, nicotine-containing vapes as a harm-reduction/cessation aid.
Red flags
- New/worsening low mood, agitation or suicidal thoughts on varenicline/bupropion — review (also consider nicotine withdrawal and underlying depression)
- Seizure history — avoid bupropion
- Red-flag respiratory symptoms (haemoptysis, weight loss) — investigate for lung cancer, do not just advise cessation
- Chest pain in a smoker — assess cardiac cause
Assessment
Differential diagnosis
- Assess dependence: time to first cigarette (within 30 min = higher dependence), number per day, previous quit attempts (Fagerstrom/Heaviness of Smoking Index)
- Identify comorbidity influencing choice: pregnancy, mental illness, cardiovascular disease, COPD
- Other tobacco/nicotine: smokeless tobacco, bidis, hookah (relevant in India), vaping
Investigations
- Smoking history: pack-years, dependence level, triggers, prior attempts and what helped/failed
- Exhaled carbon monoxide (CO) monitoring where available to assess and motivate
- Screen for and optimise smoking-related disease (COPD/spirometry, CVD risk) and mental-health comorbidity
- No routine bloods required for cessation itself
Management
- ASK about smoking at every contact and record status
- ADVISE: deliver clear, personalised very brief advice that the best thing for health is to stop, and that support makes it much more likely to succeed
- ACT: offer referral to a stop-smoking service and offer pharmacotherapy — do not just advise 'cut down'
- Agree a quit date; combine behavioural support (local service, telephone, app) with pharmacotherapy
- Offer combination NRT (long-acting patch + short-acting lozenge/gum/inhalator/spray) as first-line, or varenicline, or a nicotine-containing vape; start before or on the quit date per drug
- Address weight-gain concerns, withdrawal symptoms and relapse triggers; plan follow-up in the first weeks (highest relapse risk)
- In pregnancy: behavioural support first-line; offer NRT if needed (avoid varenicline/bupropion); CO monitoring
- Follow up to reinforce, manage side effects, and treat relapse as part of the process (most quitters need several attempts)
Drugs & doses
Disposition
Complications & pitfalls
- Nicotine withdrawal: irritability, craving, poor concentration, low mood, increased appetite/weight gain, insomnia
- Relapse (the norm, not failure — plan re-attempts)
- Drug effects: NRT skin reactions/palpitations, varenicline nausea/vivid dreams, bupropion insomnia/seizure risk
Exam pearls
- Very brief advice (Ask-Advise-Act) takes under a minute and is one of the most cost-effective interventions in medicine.
- Behavioural support + pharmacotherapy roughly triples quit rates versus willpower alone.
- Combination NRT (patch + short-acting) is more effective than a single product; varenicline is among the most effective single agents.
- A nicotine-containing vape is more effective than NRT for some smokers and is endorsed for harm reduction, but not for never-smokers or in pregnancy.
- Treat relapse as expected — most people need several attempts; keep offering support.
- Guidance: NICE NG209 (tobacco) and PHE/OHID; in India also address bidis, smokeless tobacco and gutkha.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.